Search results
Showing 106 to 120 of 1001 results for public health medicine & health
In development Reference number: GID-TA11802 Expected publication date: TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 17 September 2026
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]
In development Reference number: GID-TA11429 Expected publication date: 09 September 2026
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development Reference number: GID-TA11454 Expected publication date: 23 July 2026
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 14 July 2026
This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
In development Reference number: GID-TA11341 Expected publication date: 02 December 2026
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
In development Reference number: GID-TA11669 Expected publication date: 03 September 2026
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
In development Reference number: GID-TA11501 Expected publication date: 24 February 2027
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]
In development Reference number: GID-TA11995 Expected publication date: 03 September 2026
In development Reference number: GID-TA11340 Expected publication date: TBC
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]
In development Reference number: GID-TA11886 Expected publication date: 13 May 2027
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
In development Reference number: GID-TA10752 Expected publication date: TBC
In development Reference number: GID-TA11643 Expected publication date: TBC
In development Reference number: GID-TA11772 Expected publication date: 03 September 2026